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Background: The budding yeast Saccharomyces cerevisiae supports replication of many different RNA or DNA
viruses (e.g. Tombusviruses or Papillomaviruses) and has provided means for up-scalable, cost- and time-effective
production of various virus-like particles (e.g. Human Parvovirus B19 or Rotavirus). We have recently demonstrated
that S. cerevisiae can form single stranded DNA AAV2 genomes starting from a circular plasmid. In this work, we
have investigated the possibility to assemble AAV capsids in yeast.
Results: To do this, at least two out of three AAV structural proteins, VP1 and VP3, have to be simultaneously
expressed in yeast cells and their intracellular stoichiometry has to resemble the one found in the particles derived
from mammalian or insect cells. This was achieved by stable co-transformation of yeast cells with two plasmids,
one expressing VP3 from its natural p40 promoter and the other one primarily expressing VP1 from a modified
AAV2 Cap gene under the control of the inducible yeast promoter Gal1. Among various induction strategies we
tested, the best one to yield the appropriate VP1:VP3 ratio was 4.5 hour induction in the medium containing 0.5%
glucose and 5% galactose. Following such induction, AAV virus like particles (VLPs) were isolated from yeast by two
step ultracentrifugation procedure. The transmission electron microscopy analysis revealed that their morphology is
similar to the empty capsids produced in human cells.
Conclusions: Taken together, the results show for the first time that yeast can be used to assemble AAV capsid
and, therefore, as a genetic system to identify novel cellular factors involved in AAV biology.Introduction
Adeno-associated Virus (AAV) of the Dependovirus
genus is a member of the Parvoviridae, a family of small
and the simple viruses, whose 4.7 kb single stranded
DNA (ss-DNA) is enclosed in a non-enveloped, 20–25 nm
icosahedral capsids [1,2]. For more than 25 years, the AAV
genome has been thought to contain two genes, rep and
cap, corresponding to two open reading frames (ORFs)
and coding for four Rep proteins that regulate replication
and three VP proteins (subunits) that form capsids. Rep68
and 78 are transcribed from the p5 promoter and Rep52
and Rep40 from the p19 promoter. The p40 promoter reg-
ulates the transcription of the cap gene encoding for the
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reproduction in any medium, provided the orcapsids in the proper stoichiometry 1:1:10. This precise
VP1, 2 and 3 protein ratio is thought to be the conse-
quence of the alternative splicing required for VP1 expres-
sion and the usage of an uncommon ACG site for VP2
translation initiation [3,4]. Only recently, an alternative
AAV ORF has been mapped in the cap gene and codes for
the assembly activating protein (AAP) that promotes cap-
sid assembly in 293 T cells [5]. Rep68 and 78 participate in
the AAV DNA replication and regulate transcription from
AAV promoters and some host-cell promoters; Rep40 and
52 are involved in the generation and accumulation of sin-
gle–stranded viral genomes from double stranded replica-
tion intermediates. The coding region of AAV genome is
flanked by two 145 nucleotide long inverted terminal
repeats (ITRs). The ITRs are the only cis-acting elements
necessary for AAV replication, packaging and integration
[6]. AAV-based vectors have quickly gained great popular-
ity in gene therapy applications owing to: (i) reducedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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limited viral sequences retained in vectors and (ii) favorable
properties, such as high efficiency of transduction of post-
mitotic tissues and the long-term persistence of transgene
expression. The rising number of AAV vector-based gene
therapy trials that require high vector doses, over 1013 gen-
ome copies (g.c.)/kg of body weight [7], resulted in a var-
iety of currently existing systems for rAAV vectors’
production, based on mammalian and insect cell-factories.
In view of developing a better rAAV production technol-
ogy and creating a simple system for revealing still un-
known aspects of AAV life cycle, we have recently
established a novel, Saccharomyces cerevisiae - based re-
combinant system for ssDNA AAV2 genome formation
from the circular vectors [8]. To date, a great number of
simple, single subunit virus/nucleocapsid-like particles
(VLPs/NLPs) has been efficiently produced in yeast that
therefore has a notable value in vaccine production tech-
nologies. Apart from offering low-cost and easy to scale-
up production, the benefit of this microbial cell-factory is
its intracellular environment, highly suitable for the most
of metazoan posttranslational processing events, which
are a prerequisite for complex multimeric protein interac-
tions [9]. Recently, Rotavirus-like particles were assembled
and extracted from S. cerevisiae cells [10]. To further ex-
plore usefulness of this microbial host, this work describes
the permissiveness of S. cerevisiae intracellular environ-
ment to assembling of AAV type 2 capsids. With the pur-
pose of finding the best expression system to assemble
AAV VLPs in yeast cells, we expressed the three capsid
proteins from their natural p40 promoter or from yeast
promoters, in combination with, or without, plasmid
expressing Rep proteins. Finally, the work demonstrates
that AAV VLPs morphologically similar to those ones from
mammalian or insect cells, can be assembled in the bud-
ding yeast Saccharomyces cerevisiae.
Materials and methods
Plasmids construction
All AAV-2 sequences in the following constructs derive
from pSub201 plasmid which contains complete wild-
type AAV-2 genome [11]. YEplac181 [12]}, pYES2 (Invi-
trogen) and pGAD424 (Clontech) are vectors with LEU2
or URA3 genes for yeast selection.. To make the plasmid
YEplac.p40Cap construct, unmodified AAV2 Cap gene
was cut out from pSub201 and cloned in YEplac181 vec-
tor, using SalI and XbaI sites. For construction of the
YEplacRepCap plasmid, the AAV2 genome without ITRs
was cut out from pSub201 and cloned in the YEplac181
vector using XbaI restriction site. pYESIntronCap con-
struct was made by cutting out AAV2 Intron + Cap se-
quence (without p40 promoter) from pSub201 and
cloning this fragment in the multiple cloning site of
pYES2 vector, using HindIII and XbaI restriction sites.To make the pYESCap plasmid, VP1 cDNA (map pos-
ition 2203–4410 in wild-type AAV2 genome in the data-
base, GenBank accession no. AF043303.1) was amplified
by PCR from pSub201 using following primers:
5' - ctt ATGGCTGCCGATGGTTATCTT-3' and 5' - ctgg
TTACAGATTACGAGTCAGGTA −3.'
The sequence corresponding to the wild-type AAV2
genome is capitalized. The pYESVP1KM plasmid was
constructed by cloning modified VP1 cDNA under Gal1
promoter. The VP1 cDNA was PCR amplified from





BamHI sites (at each primer end, underlined and bold
letters) were introduced outside the VP1 expression cas-
sette for cloning in pYES2 expression plasmid. Beside
BamHI restriction site, upper primer also included 5 nu-
cleotide long yeast Kozak sequence (italicized letters)
upstream to the VP1 ATG and three modifications
(underlined letters) relative to the genuine VP sequence
in the database. The sequence corresponding to the wt
VP ORF is capitalized. After direct cloning in pYES2
BamHI site, desired clone contained Kozak sequence
upstream to the ATG start site and three mutations with
respect to genuine AAV2 sequence. The first T to C mu-
tation at position 11 eliminates an out-of frame ATG
codon by creating an ACG triplet instead. The second
modification is inactivation of the major AAV splice ac-
ceptor site, by substituting T to A at position 21 and A
to C at position 24 (numbering is as for the sequence in
the database).
Yeast strain, media
The strain RSY12 (MATa leu2-3,112 his3-11,15 URA3::
HIS3) has a complete deletion of URA3 gene which was
replaced with the HIS3 gene [13]. Complete (YPAD) and
synthetic complete (SC) mediums were prepared accord-
ing to standard protocols. Yeast was cultivated aerobic-
ally in flasks at 30°C under constant orbital shaking
(180 rpm). All yeast cultures were started from a small
inoculation (less than 100 μl per 50 ml of culture
medium) of stationary phase yeast cells. After over-night
growth, cells were collected at desired points of the
growth cycle determined by absorbance at 600 nm
(OD600): early exponential (log) growth phase of O.D600
0.7-1.0, mid-log phase yeast culture of OD600 3.5- 4.0
and early stationary phase O.D600 ~8.
The cap expressing plasmids YEplacRepCap, YEplacp40-
Cap, pYESCap and pYESIntronCap, were transformed in
yeast cells either independently or in combination, using
the standard high-efficiency, lithium chloride based
method, using single-stranded DNA as a carrier [14]. Single
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SC-leucine (SC-LEU) plates while double transformants
were selected onto SC-uracil-leucine (SC-URA-LEU) plates.
Monoclonal cultures were repeatedly grown under selec-
tion either in the solid or in the corresponding liquid
medium. The AAV protein expression was induced with ei-
ther 5% galactose or different glucose + galactose concen-
trations as stated in the results.
Protein extraction
For analysis of AAV proteins by gel electrophoresis, we
set up the novel protein extraction method named
“Optimized post-alkaline” protein extraction, which con-
sists of two cycles of extraction [8]. Briefly, aliquots cor-
responding to 100–200 × 106 cells were subjected to the
first round of extraction by the method published by
Kushnirov [15] with a small variation in the extraction
buffer (50 mM TrisHCl pH6.8, 5% glycerol, 3% SDS, 5%
β-mercaptoethanol) [15]. After centrifugation, the first
protein extract named “extract 1” was ready for further
analysis. The pellet was resuspended in harsh RIPA buf-
fer (500 mM NaCl, 50 mM Tris–HCl, 1 mM EDTA, 1%
Triton, 1% Deoxycholate (DOC), 1% SDS) and protein
solubilization further assisted by sonication. After elim-
inating the cellular impurities, the resulting proteins
fraction was named “extract 2”. Extracts 1 and 2 were
analyzed by 10% SDS-PAGE polyacrylamide gel electro-
phoresis. Protein expression was analyzed by Western
blot assay using previously described monoclonal anti-
bodies: anti-Rep monoclonal mAb 303.9, anti-VP1, 2
mAb A69, anti-VP1, 2, 3 mAb B1 [16] [17] and anti-3
phosphoglycerate kinase (3PGK, Molecular Probes) as
loading control. Like in other systems [18], for numeric
estimation of VP protein stoichiometry we used band
densitometry analysis performed by means of software
Scion Image [18].
AAV VLP extraction
Aliquots corresponding to 25 ml of yeast culture in log-
phase of growth (3 × 107 cells/ml) in medium containg 2%
glucose were diluted 10 fold and re-grown on glucose for
another 12–16 h until reached OD600 4 (mid-log phase).
Then, cells were harvested, washed and inoculated in the
induction media (e.g. 0.5% glucose +5% galactose). At dif-
ferent time points, cells were harvested, washed and fur-
ther analysed. Samples of 10 g of yeast pellet were
resuspended in 20 ml of DNS disruption buffer (500 mM
NaCl, 10mMTris pH8, 1 mM EDTA, 0.3% NP-40, 0.3%
DOC; protease-inhibitor cocktail supplemented) and
homogenized by vigorous vortexing at 4°C with 400 nm
glass beads. The crude lysate was cleared from cell-debris
and undisrupted cells by quick-low speed centrifugation.
The cleared lysate was then centrifuged at 20 000 × g, for
1 hour at 4°C ; the pellet was subjected to the secondextraction performed in the same way as the first one, with
additional 10 sonication cycles (15 sec on and 30 sec off;
15 microns amplitude) in order to enhance solubilization
of yeast produced AAV VLPs. After sonication, the cell lys-
ate was centrifuged again for 1 hour at 20,000 × g at 4°C
for elimination of insoluble material. The supernatant was
mixed with the first one and subjected to 200,000 × g
ultracentrifugation at 4°C through 40% sucrose cushion
(40% sucrose in TE-BSA buffer: 10 mM Tris pH8, 1 mM
EDTA and 0.01%BSA) for 3 h. After the centrifugation, the
pellet was resuspended in 5 ml resuspension buffer
(150 mM NaCl, 10 mM Tris–HCl pH 8, 1 mM EDTA,
5 mM MgCl2), sonicated and left in agitation for 15 h at
4°C. To improve solubilization of assembly products, the
mixture was treated with DNase (Benzonase purity grade I,
Novagen) for 30 minuntes at 37°C. Finally, the suspension
was cleared by a further centrifugation at 15000 × g for
10 minutes at 4°C. The supernatant was loaded on CsCl
gradient. CsCl was added to the sample at final density of
1.4 g/cm3, and ultracentrifugation was performed at
39,000 rpm for 48 hours, at 18°C, in a SW40-Ti rotor. 12
fractions of 1.371 to 1.430 g/cm3 densities (refractometer
readings) were collected, dialyzed against PBS buffer, and
each fraction was analyzed for VP composition by Western
blot.
Transmission electron microscopy
Fractions were placed on 200-mesh formvar carbon
coated copper grids. The sample was stained with five
drops of 2.5% (w/v) of uranyl acetate solution and incu-
bated for 2 minutes at room temperature. The excess so-
lution was removed by blotting the edge of each grid
onto filter paper and the grid was air dried for 30 min-
utes. Samples were examined with a Jeol 100 SX trans-
mission electron microscope.
Results
Capsid protein expression from the AAV p40 promoter
and influence of Rep proteins
The AAV capsid is composed of 60 subunits with a con-
stant stoichiometry of the proteins VP1, VP2 and VP3
corresponding to 1:1:10 [19,20]. By densitomeric analysis
of protein bands resolved by Western blot, the ratio of
the AAV structural proteins VP1:VP2:VP3 has been
shown to fluctuate from 1:1:8 to 1:1:20 [21]. Moreover,
in crude extracts, an average ratio ranging from 1:1:5 to
1:1:20 has been observed [18]. In order to assess the best
promoter combination to express the AAV structural
proteins at the optimal ratio, we constructed several
plasmids carrying yeast constitutive or inducible pro-
moter, or the natural AAV promoter (Figure 1, Table 1).
First of all, we studied the expression of the capsid pro-
teins under control of the AAV p40 promoter. We have
previously shown that the AAV p5 and p19 promoters
Figure 1 Schematic representation of expression cassettes constructed in this study. a) In the plasmid YEplacp40Cap, entire AAV2 cap
gene is under control of AAV2 p40 promoter. b) the YEplacRepCap plasmid contains rep and cap gene in wt configuration. c) In the vector
pYESCap, the entire cap gene is under control of Gal1 promoter. d) In the plasmid pYESIntronCap, the cap gene is placed under control of Gal1
promoter and the AAV2 intron sequence upstream the promoter. e) In the vector pYESVP1KM, the VP1 coding sequence, placed under control of
Gal1 promoter, was mutated in three sites. The point mutations were made in position 11 to eliminate an out of frame ATG codon (indicated as
M1 in the scheme), in position 21 and 24 to inactivate the major AAV splice acceptor site (indicated as M2 in the schemes). A yeast Kozak like
sequence was cloned upstream the VP1 start codon.
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[8]. This may imply that also p40 could be functional in
this simple eukaryote. We constructed a yeast multi-copy
plasmid containing unmodified AAV cap gene with all
regulative elements: p40 promoter, intron element and
polyadenylation signal (Figure 1 scheme “a”, Table 1). To
do this, the entire VP expression cassette located betweenTable 1 Plasmids constructed in this study
Plasmid Plasmid description
YEplacp40Cap wt cap sequence including p40promoter was cloned
in YEplac181 vector containing 2μm as replication
origin and LEU2 as selection marker
YEplacRepCap Entire wt AAV ORFs, rep and cap was cloned in
YEplac181 vector containing 2 μm as replication origin
and LEU2 as selection marker
pYESintron Cap Cap sequence including intron sequence (without p40)
located upstream the start codon of VP1 was cloned
downstream Gal1 promoter of pYES2 vector. The
selection marker is URA3
pYESCap Entire Cap sequence from start codon of VP1 to the
VP3 stop codon was cloned downstream Gal1
promoter of pYES2 vector. The selection marker
is URA3
pYESVP1KM VP1 coding region was cloned downstream Gal1
promoter of pYES2 vector. yeast Kozak-like element
right upstream VP1 start site. Two mutations in major
splice acceptor and a mutation in an out of frame ATG.
The selection marker is URA31428 and 4495 nucleotides of AAV genome (numbering is
as for the sequence under GenBank accession no.
AF043303.1) was cloned into YEplac181. The resulting
plasmid named YEplacp40Cap has the yeast 2-micron ori-
gin of replication which constantly provides 20–50 copies
of the recombinant gene per haploid yeast genome [22].
Plasmid YEplacp40Cap was transformed in the haploid
yeast strain RSY12. Growth curves carried out at 30°C
under constant shaking of YEplacp40Cap and YEplac181
control plasmid-transformed cells were similar, with
doubling time of about 2.7 h, when 2% glucose was used
as the carbon source. At 4 different time points, cells
were collected and subjected to protein extraction. The
first two time points correspond to early exponential/
logarithmic (log) growth phase, the third one to mid-log
and the fourth one to the late-log phase. Cap protein ex-
pression was analyzed by Western blot analysis of total
cell lysates at each of these time points (Figure 2A). As
shown in the Figure 2A, the only capsid protein detected
is VP3. Since the concentration of VP1 and VP2 is
expected to be 10 times lower than that of VP3, it is
likely that the proteins are present in an amount too low
to be detected by western blot. VP3 accumulated with
time, following exponential cell growth and biomass ac-
cumulation (the maximal amount of protein was
extracted from mid-late exponential growth phases). The
majority of VP3 protein was found in insoluble fraction
Figure 2 Expression of AAV2 Cap and Rep proteins from natural promoters. Transformed RSY12 cells were grown in liquid selective
medium until cultures reached different densities determining different growth phases (early→ late log) indicated on the top. Equal amounts of
total cell lysate, extract 1 and 2 (~50 μg each), obtained from 2 × 108 cells at each phase, were analyzed by Western blot analysis with antibodies
indicated on the left: mAb B1 to detect Cap proteins (A and C), mAb 303.9 to detect Rep proteins (B) and mAb Anti-3PGK to detect constitutive
yeast protein PGK (Phospho-Glicerate-Kinase). (A): VP3 was the only capsid protein detected in the samples from YEplacp40Cap transformed cells;
thehighest level was detected in the mid-log phase extracts. (B): All four Rep proteins were detected in the samples from YEplacRepCap
transformed cells; the highest level was obtained in the late-log phase extracts. (C): late-log phase extracts from YEplacRepCap cells were also
analyzed for Cap protein expression and compared with late-log phase extracts from YEplacp40Cap cells; only VP3 was detected in both samples.
Denatured, 293 T-cell-derived, AAV2 capsids were used as positive control (+ control) for defining VPs (A, C).
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This fraction of the total cellular proteins was designated
as “extract 2”.
In the natural background, the expression of VP pro-
teins is regulated by Rep68 and 78 proteins through the
p40 promoter activity and mRNA maturation [23]. The
first process is dependent on sequences associated with
p5 and p19 promoter elements [24], the second one is
achieved when the AAV2 intron element is paired to its
natural promoter and extended polyadenylation signal
[23]. In order to assess if the expression of Rep could in-
crease the expression of VP1, 2, and 3, we introduced
rep and cap gene in their wild type genomic configur-
ation into the yeast vector YEplac181, thus keeping p5,
p19, p40, intron and the polyadenylation signal. The
resulting plasmid was named YEplacRepCap (Figure 1,
scheme “b”). RSY12 cells carrying this construct were
grown and collected at two different growth phases,
mid-log and late-log phase, and respective protein
extracts analyzed by Western blot for Rep and Capprotein expression. All the Rep proteins, namely Rep40,
52, 68 and 78 were expressed and achieved the maximal
level at the late-log phase (Figure 2B). Insoluble protein
fraction (extract 2) was more abundant in all Rep pro-
tein species. To investigate the influence of Rep proteins
upon the VP expression, we compared the Western blot
results for VPs produced in these cells with the ones
from YEplacp40Cap transformants which do not express
Rep. VP3 was the only capsid protein detected without a
notable difference in its intracellular level and distribu-
tion to extracts 1 and 2 (Figure 2C), indicating that Rep
proteins had no influence on VP expression in yeast.
Inducible Yeast Promoter for Regulation of AAV
Structural Protein Expression
The galactose inducible promoter of the GAL1 gene
(pGal1) can be finely regulated by the amount of induct-
ing agent in the growth medium and by varying the in-
duction time [25,26]. Since VP2 was shown to be non
essential for infectivity of the AAV virions [27,28],
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was the principal condition for developing yeast-cell
based system for production of the wt like AAV-capsids.
We made various constructs based on the yeast expres-
sion vector pYES2 which contains two potent gene ex-
pression regulators, the pGal1 and the cyc1 terminator
(Table 1). To check weather all AAV capsid proteins
could be detected simultaneously, these vectors were
transformed in yeast and transformants were selected as
already reported. Moreover, we made the vector named
pYESCap, where the Cap from the VP1 start codon was
cloned downstream pGal1 (Figure 1 scheme “c”).Figure 3 Expression of AAV2 structural proteins from yeast the galac
were first grown for 12 h in glucose and then transferred to galactose med
each of these time points and equal amounts of the total cell lysates (~50
mAb B1. VP3 was the only Cap protein detected and only in the extract 2
samples, diminished after 4 h induction and was no more detectable upon
were exposed to galactose for different times, as indicated on the top, and
analyzed for Cap protein expression using mAb B1. The majority of VP1 pro
transformed with empty vector, pYES2 were used as negative controls (−coSurprisingly, neither VP1 nor VP3 was detected in the
extracts from yeast cells carrying the pYESCap ( Figure 1
scheme “c”; data not shown). On the other hand,
extracts from yeast cells carrying the vector pYESIntron-
Cap containing the intron sequence upstream VP1 start
codon (Figure 1 scheme “d” ), the only protein detected
was again VP3 and its highest amount was detected in
the extract of the cells grown on glucose (Figure 3A).
After the carbon source switch to galactose, some back-
ground VP3 level was still observed after 4 h of galactose
growth and completely vanished after 8 h in galactose
(Figure 3A). The decrease of the amount of VP3 intose-inducible promoter Gal1. (A): pYESIntronCap-transformed cells
ium for 4 and 8 h of induction. Mid-log phase cells were collected at
μg), were analyzed for Cap protein expression by Western blot using
(insoluble fraction). Its relative amount was the highest in 12 h glucose
8 h of galactose induction. (B): pYESVP1KM-transformed yeast cells
equal amount of corresponding protein (~50 μg) extracts was
teins were found in extract 2 (insoluble fraction). Extracts from cells
ntrol).
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since no toxicity-related phenotype (e.g. decreased
growth rate or abolished growth) was observed in
galactose-grown cells. More likely, carbon source ex-
change could be quite stressful for the yeast cells.
Studied of AAV protein expression in insect cell sys-
tem demonstrated that the introduction of some modifi-
cations in the coding sequences could improve VP
expression [29]. So we made another pYES2-based con-
struct, named pYESVP1KM (Figure 1 scheme “e”) that
lacks AAV intron and contains VP1 coding region down-
stream to pGal1 and yeast Kozak-like element right up-
stream of VP1 start site. In addition, we introduced two
site specific mutations in the VP1 sequence: a mutation
in the major AAV splice acceptor site to eliminate the
possible splicing from the VP1 mRNA and an out-of-
frame ATG mutation in the close proximity to VP1
translational start site to prevent interference with the
choice of the right reading frame.
Western blot analysis of protein extracts from
pYESVP1KM transformed cells showed that galactose
induction caused gradual increase in VP1 protein ex-
pression with the highest level achieved after around 7 h
of induction (Figure 3B). VP1 was the only capsid pro-
tein detected in these cells. The majority of VP1 protein
was recovered from insoluble fraction of the total cell
proteins (extract 2, Figure 3B).
Modulation of VP1/VP3 expression pattern as a
prerequisite for efficient capsid assembly
Since we obtained detectable expression of VP3 from the
vector YEplacp40Cap, and VP1 from pYESVP1KM, we
transformed yeast cells with these plasmids to achieve
simultaneous high level expression of AAV capsid pro-
teins. We modulated their relative amount by growing
the co-transformed clones, first in glucose and, then, in
galactose for different induction times. In parallel, we
also tested the clones co-transformed with pYESVP1KM
and YEplacRepCap to assess if Rep could affect the VP
expression pattern. As expected, Western blot analysis
showed that both co-transformed cell clones (Rep posi-
tive and Rep negative) produced VP3 protein after
growth in glucose, while VP1 expression was induced
only after the cell growth in galactose containing
medium (Figure 4A). The induction was initially done for
7 h since VP1 was previously shown (Figure 3B) to reach
its maximum level at this time point. However, at the
end of galactose induction, VP3 protein is not detectable
in the cells that do not express Rep (Figure 4A, Cap +
VP1KM co-transformed clones) and was hardly detect-
able in the presence of Rep protein (Figure 4A, RepCap +
VP1KM co-transformed clones). This slight difference
cannot be only attributed to Rep proteins which, indeed,
were efficiently expressed throughout the whole culture(at least Rep78 and 52), both during glucose and galact-
ose growth (Figure 4B). The decrease in the VP3 protein
level after the growth in galactose may imply that de novo
VP3 synthesis is either prevented or reduced when gal-
actose is used as a carbon source, resulting in VP3 “dilu-
tion” in the growing cell population. To overcome VP3
decrease and set up the best conditions for production of
VP3 and VP1 proteins in the optimal ratio (similar to the
one found in the wild type AAV capsids), we gradually
decreased the induction time in galactose and analyzed
VP1:VP3 ratio at different time points as indicated in the
Figure 4C (the densitometry for each induction time is
reported in the table below the western blot). VP1 ex-
pression was observed already 40 minutes after galactose
induction (Figure 4C, lane 2) and increased with time.
After 4 hours of induction, gradual increase of VP1 was
followed by decrease in the VP3 level (Figure 4C, lane 4),
which was no longer detectable after 8 h of induction,
when VP1 expression reached its maximum level
(Figure 4C, lane 5). The relative VP1:VP3 ratios were cal-
culated from corresponding band intensities at each time
point and the values are presented in the Figure 4C. By
decreasing induction time to 40 minutes, we obtained
the VP1:VP3 ratio of 1:9 (Figure 4C, lane 2). This VP stoi-
chiometry is reported to be in the optimal range to form
AAV capsids [18]. Nevertheless, such a short induction
time makes the experimental reproducibility very difficult
to achieve, so we tried the strategy of “glucose + galact-
ose mixed cultures” which enabled fine tuning of VP1:
VP3 ratio. When both nutrients are present in high con-
centration, glucose is used by cells as preferable carbon
source. In other words, yeast starts utilizing galactose
after the glucose concentration in the medium is com-
pletely exhausted [30]. After 12 h growth in 2% glucose
medium, cells were transferred to the medium containing
1.5% glucose and 2.5% galactose (named “high glucose,
high galactose”) and VP1:VP3 ratios tested at different
induction times. The best ratio was reached after 9 h
(Figure 5A). After 18 hour induction the VP1 protein
level increased and the VP3 decrease. Based on these
results, we hypothesized that during the VP1 induction
in 5% galactose, glucose should be kept at residual con-
centration to ensure the constitutive expression of VP3.
Therefore, by decreasing the glucose concentration to
0.5%, the optimal VP1:VP3 ratio could be obtained at
earlier time points with respect to “high glucose (glu)-
high galactose (gal)” conditions. In particular, yeast
grown in 2% glucose for 18 hours were transferred in the
medium containing 0.5% glucose and 5% galactose,
designated as “low glu-high gal” medium. The relative
VP1 and VP3 protein level was analyzed by Western blot
in extracts from yeast cells collected at different induc-
tion time points (Figure 5B). The best VP1:VP3 ratio
(1:8) was obtained after 4.5 h of induction (Figure 5B,
Figure 4 VP1-VP3 expression pattern in co-transformed yeast clones. Cells co-transformed with YEplacp40Cap and pYESVP1KM (Cap +
VP1KM clone) (A) and Rep expressing cells co-transformed with YEplacRepCap and pYESVP1KM (RepCap + VP1KM) (B), were grown on glucose
and then transferred to galactose for induction. Equal amounts of total cellular proteins (extracts 1 + 2) were analyzed by Western blot, using
mAb B1 to detect VP proteins. (A): VP3 was detected in both yeast clones after 12 h growth in glucose and it decreased along with VP1
induction upon 7 h in galactose. (B): Extracts from RepCap + VP1KM clones were analyzed for Rep protein expression before (12 h glucose) and
after 7 h galactose growth, using mAb 303.9. Similar amounts and distribution of Rep isoforms to extracts 1/2 were detected in glucose and
galactose samples. Extracts from cells co-transformed with empty vectors, YEplac181 and pYES2 were used as -control. (C): Lanes 0–5: VP1-VP3
expression pattern in total cell-extracts derived from RepCap + VP1KM clones before induction (“0” time point) and at various times of galactose
induction. VP1:VP3 ratios are determined band densitometry and shown in the table below. Numbers represent the density expressed in arbitrary
unit detected by the analysis software described in materials and methods. Results are reported as mean of at least three independent
experiments ± standard error. The best ratio was obtained after 40 minutes of galactose induction.
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reported in the table below the Western blot). When we
increased the induction time, VP1 started to accumulate
while VP3 decreased leading to a non optimal ratio
(Figure 5B, lane 5).
Assembly and characterization of VLPs
To test whether yeast assembled VP1 and VP3 into virus-
like particles when these proteins are expressed at the opti-
mal ratio, 3 g of the yeast cell biomass (~400 × 108 cells)
carrying the YEplacRepCap and the pYESVP1KM plasmid
were lysed and processed under non-denaturing conditions.Cell lysates were subjected to high speed centrifugation in
40% sucrose cushion (as reported in the materials and
methods) and the resulting fractions, the pellet (Figure 6A,
lane 2) and the supernatant (Figure 6A, lane 3) were ana-
lyzed for the presence of VP proteins by Western blot. VPs
were found in the pellet (Figure 6A, lane 2) and not in the
supernatant fraction (Figure 6A, lane 3). Surprisingly, be-
side VP1 and VP3, Western blot analysis for the first time
revealed the presence of VP2 protein. This result was inter-
preted in terms of low overall VP2 expression whose con-
centration in the total cell-lysate (Figure 6A, lane 1) was
under Western blot detection limit. To confirm that the
Figure 5 VP1:VP3 optimization with “low glucose-high galactose” induction strategy. (A) After over-night growth on glucose,
YEplacRepCap + pYESVP1KM (RepCap + VP1KM) and YEplacp40Cap + pYESVP1KM (Cap + VP1KM) yeast clones were induced in the presence of
high glucose (1.5%) and high galactose (2.5%) concentration. VP expression was analyzed by Western blot at three different time points before
induction (“0 h”) and after 9 h and 18 h. There was no significant difference in VP1/VP3 expression pattern between clones and the best ratio
(1:9), was detected for 9 h induction time for yeast cells co-transformed with YEplacRepCap and pYESVP1KM (RepCap + VP1KM) . (B) After
overnight growth on glucose, YEplacRepCap and pYESVP1KM (RepCap + VP1KM) co-transformed yeast cells were induced in the medium
containing low glucose (0.5%) and high galactose (5%) concentration. Lanes 0–5: VP1-VP3 expression pattern was determined by Western blot
analysis before induction (lane1,“0 h”) and after 5 different induction periods (lane 2, 4.5 h; lane 3, 6 h; lane 4, 7 h; lane 5, 8 h, lane 6, 9 h) . VP1:
VP3 ratios, calculated by means of band densitometry, are presented in the table below. Numbers represent the density expressed in arbitrary
unit detected by the analysis software described in materials and methods. Results are reported as mean of at least three independent
experiment ± standard error. The best ratio was obtained after 4.5 h induction in 0.5% glucose + 5% galactose medium (lane 2).
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through 40% sucrose cushion, resembled their relative
intracellular levels, cells were induced under conditions
that yielded VP1 and VP3 in the ratio different from the
“optimal” one. For instance, after 7 h of induction in
0.5% glucose + 5% galactose medium, VP1:VP3 in the
ultracentrifugation pellet was 1:3 (Figure 6A, lane 6)
being almost identical to the ratio in the total cell lysate,
1:3.3 (Figure 6A, lane 5). Again, in the ultracentrifugation
pellet is detected also VP2 protein (Figure 6A, lane 6).
Since both constructs used for VP1 and VP3 expression
contained unmodified VP2 ORF, comprised in, and in
frame with VP1 ORF, we were curious to investigate the
origin of VP2 protein. To do this, yeast cells transformed
with pYESVP1KM or YEplacRepCap, were induced andprocessed for ultracentrifugation as double-transformed
yeast clones. The two corresponding pellet fractions were
analyzed for VP proteins composition by Western blot
(Figure 6B, lanes 3 and 4). Total cell extracts were analyzed
in parallel to monitor the relative intracellular levels of VPs
(Figure 6B, lanes 1 and 2). No VP2 was detected neither in
the total protein extract derived from YEplacRepCap trans-
formed cells (Figure 6B, lane 1) nor in the one from the
pYESVP1KM clones (Figure 6B, lane 2). The VP compos-
ition in the ultracentrifugation pellet derived from YEpla-
cRepCap clones (Figure 6B, lane 3) was identical to the one
in its total cell extract: the only protein detectable was
VP3. In the pellet from pYESVP1KM–transformed cells,
all three VP proteins were detected, suggesting that VP2
and VP3 are synthesized from this construct at low levels
Figure 6 Concentration of AAV2 capsid like-structures by high-speed ultracentrifugation through 40% sucrose-cushion. (A):
YEplacRepCap + pYESVP1KM (RepCap + VP1KM)co-transformed yeast cells induced for 4.5 h (lanes 1–4) or 7 h (lanes 5 and 6) in 0.5% Glu + 5%
Gal medium were subjected to a small scale (2 x 108 cells) - protein extraction yielding total cell lysate (lanes 1 and 5) and to a large scale
extraction (~400 x 108 cells) (lanes 2, 3, 4 and 6) under non-denaturing conditions yielding the “native extract“ which was subjected to
ultracentrifugation. As indicated on the bottom, the total cell lysate (lanes 1 and 5) and the resulting ultracentrifugation fractions, the supernatant
(lane 3) and the pellet (lanes 2 and 6), were analyzed for the presence of VP proteins by Western blot. The antibody mAb B1 recognized only VP1
ad VP3 in the total cell lysate and all three VPs in the pellet fraction. The VP ratios in the total cell lysate were 1:8 (lane 1) and 1:3.3 (lane 5). The
VP ratios in the pellet resulting from ultracentrifugation were 1:1.2:6.5 (lane 2), 1:3 (lane 6). The pellet obtained by ultracentrifugation of the
extracts derived from cells co-transformed with empty vectors, YEplac181 and pYES2, was used as negative control (lane 4). Positive control is
loaded in lane 7. (B): Cells transformed with YEplacRepCap (RepCap, lane 1 and 3) or with pYESVP1KM (VP1KM, lane 2 and 4) were induced for
7 h in 0.5% glucose + 5% galactose medium. All cells were processed as described in (A). VP proteins in the total cell lysates (lanes 1 and 2) and
the ultracentrifugation pellet (lanes 3 and 4) were identified by Western blot analysis with mAb B1. The relative VP ratio is 1:0.25:0.9 for sample
loaded in lane 4. No proteins were loaded in lanes marked with *. In the lane 5 the positive control was loaded.
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pellet was 1: 0.25: 0.9. As expected, the relative amount of
VP2 was lower than VP1, whereas the level of VP3 was al-
most equal to VP1 protein, in divergence with its low over-
all intracellular level, undetectable by Western blot
(Figure 6B, lane 2). This result suggest that even when the
concentration of VP was too small for their detection by
Western blot, they could assemble into VLPs.
To better understand if yeast forms VLPs, samples
corresponding to 10 g of yeast biomass (YEplacRepCap
and pYESVP1KM co-transformed cells grown under
“optimal conditions”) were analyzed upon fractionationby high speed ultracentrifugation in CsCl density gradi-
ent. After ultracentrifugation, 12 fractions were col-
lected, dialyzed against PBS and analyzed by the
Western blot (Figure 7A). In the 1st fraction (of the lowest
density), only VP3 protein was detected (Figure 7A, f1).
Fractions 2, 3 and 4 (Figure 7A, f2, f3, f4) contained al-
most equal amounts of VP2 and VP3, but VP1 is below
the detection limit. Fractions 8–11 (Figure 7A, f8, f9, f10,
f11) contained all three VPs. Only VP3 was detected in
f12. Finally, the VP proteins were also detected in the
pellet CsCl fraction (f13) (data not shown) and hence
not recovered in the other fractions. Importantly, the
Figure 7 Isolation of AAV2 capsid like-structures by ultracentrifugation in CsCl-gradient. Native protein extracts derived from ~ 0.5x1012
YEplacRepCap + pYESVP1KM (RepCap + VP1KM)co-transformed yeast cells, induced under optimal conditions, were subjected to 40% sucrose
cushion-ultracentrifugation and the pelleted material was further fractionated in CsCl gradient by 48 h,. (A): 12 CsCl fractions of increasing
densities were recovered and analyzed for the presence of VP proteins by Western blot with mAb B1. Only VP positive fractions are presented.
Structures recovered in fractions 8–11 had VP compositions that most closely resembled the one of wt capsids. Denatured 293 T-cell derived
AAV2 capsids were used as positive control for defining VPs. (B): Fractions of similar densities were united and subjected to TEM analysis. (i)
Capsid-like structures of ~20 nm size identified in fraction f8 + f9 are shown and compared with 293 T –derived AAV2 empty capsids (ii). Scale
bar is 40 nm. (C): 3 fraction pairs that gave positive results in TEM were spotted on the nitrocellulose membrane in three quantities indicated on
the right side bar and analyzed for the presence of AAV capsids with the capsid-specific mAb A20 antibody. The strongest signal (which indicates
the greatest number of capsids) was detected in the fraction f8 + f9. As negative control of the assay, the same number of cells co-transformed
with empty vectors, YEplac181 and pYES2, were processed as described in (A) and the obtained CsCl fractions of the corresponding densities
were incubated with A20 antibody. The name of fractions and relative density are indicated.
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showed very low level of VP proteins and no contaminant
proteins corresponding to the fractions f8-f12 (data not
shown). This result suggest that a very low amount of
VLPs was purified. Altogether, our results indicate that
yeast is able to assemble AAV VLPs.
To finally demonstrate that yeast supports AAV capsid
assembly, small aliquots of fractions of similar densities
derived from CsCl gradient fractionation were mixed and
analyzed in transmission-electron microscopy (TEM) for
the presence of capsid-like structures (Figure 7B). Capsid-like structures were observed in f8-f11 fractions, in the
density range of 1.386-1.394 g/cm3, containing the three
capsid proteins in the relative frequencies similar to the
ones of wt AAV-2 capsids. Figure 7B-i shows that yeast-
cell derived capsid-like structures observed in fraction f8
combined with f9 (f8 + f9) were morphologically similar
to the ones obtained from 293 T cells (Figure 7B-ii, a kind
gift from J. Kleinschmidt). The density of capsid positive
fractions is not corresponding to the expected ones for
empty AAV capsids produced in mammalian cells (1.32-
1.35 g/cm3) [19,31], but is very similar to the density
Backovic et al. Microbial Cell Factories 2012, 11:124 Page 12 of 14
http://www.microbialcellfactories.com/content/11/1/124reported for AAV empty particles from insect cells
(1.38 g/cm3) [32].
To support electron microscopy results, the “VLP-
positive” fractions with similar densities were combined
resulting in f3 + 4, f10 + f11, f8 + f9 fractions and ana-
lyzed in Dot-Blot assay to assess immunoreactivity of
yeast-derived particles with anti-capsid A20 antibody.
A20 is a widely used monoclonal antibody which specif-
ically binds a conformational AAV-2 capsid epitope and
does not recognize native capsid subunits and other as-
sembly intermediates [16] [17]. Interestingly, all three
fractions showed reactivity to A20 antibody, even f3 + 4
fraction which in western blot analysis showed low level
of VP2 and VP3 and VP1 was not detected (Figure 7A).
The highest concentration of A20-reactive virus-like par-
ticle was observed in f8 + f9 fraction (Figure 7C). This
result suggests that the VP proteins assembled in the
correct way in yeast.
Discussion
In line with raising importance of yeast cell-factories in
production of VLPs used in vaccinology, diagnostics,
sero-epidemiology, nanotechnology and gene transfer,
we created the S. cerevisiae expression system for study-
ing the permissiveness of its intracellular background to
self-assembly of AAV2 capsid proteins in virus-like par-
ticles with properties similar to those of AAV capsids
produced in mammalian or insect cells. In mammalian
cells, the optimal ratio of AAV VPs proteins to obtain
high amounts of particles was achieved by placing the
rep ORF under a strong promoter and the cap ORF
under the control of its natural promoter (p40) [33]. In
insect cells, high AAV titers have been obtained using
specific baculovirus promoters [34].
In order to achieve the best VP protein ratio for the
correct assembly in yeast, two requirements has to be
satisfied: the simultaneous expression of at least two
out of three AAV structural proteins, VP1 and VP3 and
the intracellular stoichiometry of these proteins in yeast
cells should be similar to that one found in the particles
derived from mammalian or insect cells. We con-
structed one plasmid carrying modified AAV2 Cap ORF
under inducible yeast promoter Gal1and the another
vector expressing VP3 from the genuine AAV cap gene
under its cognate p40 promoter. VP3 protein expres-
sion from AAV p40 promoter in yeast cells resembled
the expression profile of yeast glycolytic-promoters,
characterized by the positive correlation with the cell
growth rate during glucose-based growth [35].The best
results in terms of “optimal” VP1:VP3 ratio and experi-
mental reproducibility were obtained when glucose was
kept at low concentration (0.5%) in the galactose rich
(5%) medium. The ratio of VP proteins in cell extracts
has been suggested to correlate with VLP compositionindicating that the optimal level of proteins is required
for the VLP correct assembly [36]. Therefore, after
4.5 hour induction, we have obtained the best VP1:VP3
ratio and we were able to extract VLPs from yeast. Al-
though the CsCl fractions did not have the expected
buoyant density, all the VPs proteins were detected and
the VLPs were composed of VP1, VP2 and VP3. The
buoyant density of infectious AAV particles is reported
to range from 1.39 to 1.42 g/cm3 [31]. Empty or partial
empty AAV particles have been shown to have a dens-
ity corresponding to 1.32 and 1.35 g/cm3 [31]. On the
other hand, AAV empty particles purified from insect
cells have a density of 1.38 g/cm3 that is not very differ-
ent from the buoyant density of VLPs from yeast [32].
These light particles appear empty at the electron
microscope and have been reported to have either no
DNA or DNA of less that genome length; the density
of the AAV particles is generally correlated with the
size of the encapsidated DNA [37]. We can suppose
that higher density of “empty” VLPs from yeast is due
to the presence of small yeast DNA fragments inside.
This is very difficult to demonstrate since we have a
low amount of CsCl fractions because most VLPs
remained in the pellet. We have further characterized
by electron microscopy VLP fractions with buoyant
densities ranging from 1.386 to 1.392 g/cm3. Results
indicated that the VLPs from yeast are morphologically
and immunologically similar (reactivity to A20 anti-
body) to the particles extracted from human cells (see
Figure 7B and C). Our study provides the first experi-
mental evidence that the yeast Saccharomyces cerevisiae
is able to form AAV VLPs. However, a certain amount
of VPLs was not recovered after ultracentifugation. A
similar situation was seen in the first baculovirus-insect
cell VP-expression system made by Ruffing et al. [38]
where the three VPs were expressed from separated
ORFs (cDNAs), each one carrying mutations in other
two VP-start codons. Moreover, in HeLa cells it has
been observed that not assembled VP monomers can
associate with cellular structures has been previously
documented in vitro and [39].
This work demonstrated that S. cerevisiae assembles
AAV proteins into VLPs and opens new frontiers to-
wards the use of yeast in the rAAV production. Together
with our pioneer demonstration of ss rAAV genomes
production in this microbial system [8], it leads the fu-
ture research toward studying yeast permissiveness to
packaging of ss rAAV genomes in preformed capsids.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
AB performed all molecular biology experiments and analyzed the resulting
data; TC and LZ carried out the VLP purification; MG analysed the data
concerning the CsCl gradient; AS performed the electron microscopy of the
Backovic et al. Microbial Cell Factories 2012, 11:124 Page 13 of 14
http://www.microbialcellfactories.com/content/11/1/124VLP; AG conceived the study; AB and TC edited the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
We thank Robert Schiestl for the yeast strain. We also are grateful to Jürgen
Kleinschmidt for helpful suggestions and for sending the purified AAV
vectors. We would like to dedicate this paper to our colleague and friend
Arturo Falaschi who suddenly died on the 2nd of June 2010. He really
believed in this project and strongly stimulated us to go on with
experiments. The work was supported by the Grant n. GGP09166 assigned
from Telethon-Italy to AG.
Author details
1Laboratorio di Tecnologie Genomiche, Istituto di Fisiologia Clinica, CNR, Pisa, Italy.
2Scuola Normale Superiore Pisa, Pisa, Italy. 3Sezione di Biologia e Genetica,
Dipartimento di Morfologia Umana e Biologia Applicata, Università Pisa, Pisa, Italy.
4Molecular Medicine Laboratory, International Centre for Genetic Engineering and
Biotechnology (ICGEB), Trieste, Italy.
Received: 23 March 2012 Accepted: 6 August 2012
Published: 11 September 2012
References
1. Lukashov VV, Goudsmit J: Evolutionary relationships among parvoviruses:
virus-host coevolution among autonomous primate parvoviruses and
links between adeno-associated and avian parvoviruses. J Virol 2001,
75(6):2729–2740.
2. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M: Recent
developments in adeno-associated virus vector technology. J Gene Med
2008, 10(7):717–733.
3. Van Vliet KM, Blouin V, Brument N, Agbandje-McKenna M, Snyder RO: The
role of the adeno-associated virus capsid in gene transfer. Methods Mol
Biol 2008, 437:51–91.
4. Becerra SP, Koczot F, Fabisch P, Rose JA: Synthesis of adeno-associated virus
structural proteins requires both alternative mRNA splicing and alternative
initiations from a single transcript. J Virol 1988, 62(8):2745–2754.
5. Sonntag F, Schmidt K, Kleinschmidt JA: A viral assembly factor promotes
AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 2010,
107(22):10220–10225.
6. Wu Z, Asokan A, Samulski RJ: Adeno-associated virus serotypes: vector
toolkit for human gene therapy. Mol Ther 2006, 14(3):316–327.
7. Qiao C, Li J, Zheng H, Bogan J, Yuan Z, Zhang C, Bogan D, Kornegay J, Xiao
X: Hydrodynamic limb vein injection of adeno-associated virus serotype
8 vector carrying canine myostatin propeptide gene into normal dogs
enhances muscle growth. Hum Gene Ther 2009, 20(1):1–10.
8. Cervelli T, Backovic A, Galli A: Formation of AAV single stranded DNA
genome from a circular plasmid in Saccharomyces cerevisiae. PLoS One
2011, 6(8):e23474.
9. Quartley E, Alexandrov A, Mikucki M, Buckner FS, Hol WG, DeTitta GT,
Phizicky EM, Grayhack EJ: Heterologous expression of L. major proteins in
S. cerevisiae: a test of solubility, purity, and gene recoding. J Struct Funct
Genomics 2009, 10(3):233–247.
10. Rodriguez-Limas WA, Tyo KE, Nielsen J, Ramirez OT, Palomares LA:
Molecular and process design for rotavirus-like particle production in
Saccharomyces cerevisiae. Microb Cell Fact 2011, 10:33.
11. Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of adeno-associated
virus into pBR322: rescue of intact virus from the recombinant plasmid
in human cells. Proc Natl Acad Sci U S A 1982, 79(6):2077–2081.
12. Gietz RD, Sugino A: New yeast-Escherichia coli shuttle vectors
constructed with in vitro mutagenized yeast genes lacking six-base pair
restriction sites. Gene 1988, 74(2):527–534.
13. Schiestl RH, Petes TD: Integration of DNA fragments by illegitimate
recombination in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 1991,
88(17):7585–7589.
14. Schiestl RH, Dominska M, Petes TD: Transformation of Saccharomyces
cerevisiae with nonhomologous DNA: illegitimate integration of
transforming DNA into yeast chromosomes and in vivo ligation of
transforming DNA to mitochondrial DNA sequences. Mol Cell Biol 1993,
13(5):2697–2705.
15. Kushnirov VV: Rapid and reliable protein extraction from yeast. Yeast
2000, 16(9):857–860.16. Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA: Subcellular
compartmentalization of adeno-associated virus type 2 assembly. J Virol
1997, 71(2):1341–1352.
17. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA:
Monoclonal antibodies against the adeno-associated virus type 2
(AAV-2) capsid: epitope mapping and identification of capsid domains
involved in AAV-2-cell interaction and neutralization of AAV-2
infection. J Virol 2000, 74(19):9281–9293.
18. Aucoin MG, Perrier M, Kamen AA: Critical assessment of current adeno-
associated viral vector production and quantification methods. Biotechnol
Adv 2008, 26(1):73–88.
19. Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmidt J:
Titration of AAV-2 particles via a novel capsid ELISA: packaging of
genomes can limit production of recombinant AAV-2. Gene Ther 1999,
6(7):1322–1330.
20. Kronenberg S, Kleinschmidt JA, Bottcher B: Electron cryo-microscopy and
image reconstruction of adeno-associated virus type 2 empty capsids.
EMBO Rep 2001, 2(11):997–1002.
21. Girod A, Wobus CE, Zadori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA,
Hallek M: The VP1 capsid protein of adeno-associated virus type 2 is
carrying a phospholipase A2 domain required for virus infectivity. J Gen
Virol 2002, 83(Pt 5):973–978.
22. Romanos MA, Scorer CA, Clare JJ: Foreign gene expression in yeast: a
review. Yeast 1992, 8(6):423–488.
23. Qiu J, Pintel D: Processing of adeno-associated virus RNA. Front Biosci
2008, 13:3101–3115.
24. Qiu J, Pintel DJ: The adeno-associated virus type 2 Rep protein regulates
RNA processing via interaction with the transcription template. Mol Cell
Biol 2002, 22(11):3639–3652.
25. Kim MD, Lee TH, Lim HK, Seo JH: Production of antithrombotic hirudin in
GAL1-disrupted Saccharomyces cerevisiae. Appl Microbiol Biotechnol 2004,
65(3):259–262.
26. Friedl AA, Kiechle M, Maxeiner HG, Schiestl RH, Eckardt-Schupp F: Ty1
integrase overexpression leads to integration of non-Ty1 DNA fragments
into the genome of Saccharomyces cerevisiae. Mol Genet Genomics 2010,
284(4):231–242.
27. Grieger JC, Johnson JS, Gurda-Whitaker B, Agbandje-McKenna M, Samulski
RJ: Surface-exposed adeno-associated virus Vp1-NLS capsid fusion
protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-
only capsids but not that of fivefold pore mutant virions. J Virol 2007, 81
(15):7833–7843.
28. Warrington KH Jr: Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S,
Muzyczka N: Adeno-associated virus type 2 VP2 capsid protein is
nonessential and can tolerate large peptide insertions at its N terminus.
J Virol 2004, 78(12):6595–6609.
29. Urabe M, Ding C, Kotin RM: Insect cells as a factory to produce adeno-
associated virus type 2 vectors. Hum Gene Ther 2002, 13(16):1935–1943.
30. Demir O: Aksan Kurnaz I: An integrated model of glucose and galactose
metabolism regulated by the GAL genetic switch. Comput Biol Chem
2006, 30(3):179–192.
31. Tenenbaum L, Lehtonen E, Monahan PE: Evaluation of risks related to the
use of adeno-associated virus-based vectors. Curr Gene Ther 2003,
3(6):545–565.
32. Negrete A, Kotin RM: Strategies for manufacturing recombinant
adeno-associated virus vectors for gene therapy applications
exploiting baculovirus technology. Brief Funct Genomic Proteomic
2008, 7(4):303–311.
33. Grimm D, Kern A, Rittner K, Kleinschmidt JA: Novel tools for production
and purification of recombinant adenoassociated virus vectors. Hum
Gene Ther 1998, 9(18):2745–2760.
34. Virag T, Cecchini S, Kotin RM: Producing recombinant adeno-associated
virus in foster cells: overcoming production limitations using a
baculovirus-insect cell expression strategy. Hum Gene Ther 2009,
20(8):807–817.
35. Brauer MJ, Huttenhower C, Airoldi EM, Rosenstein R, Matese JC, Gresham D,
Boer VM, Troyanskaya OG, Botstein D: Coordination of growth rate, cell
cycle, stress response, and metabolic activity in yeast. Mol Biol Cell 2008,
19(1):352–367.
36. Hoque M, Shimizu N, Ishizu K, Yajima H, Arisaka F, Suzuki K, Watanabe H,
Handa H: Chimeric virus-like particle formation of adeno-associated virus.
Biochem Biophys Res Commun 1999, 266(2):371–376.
Backovic et al. Microbial Cell Factories 2012, 11:124 Page 14 of 14
http://www.microbialcellfactories.com/content/11/1/12437. de la Maza LM, Carter BJ: Molecular structure of adeno-associated virus
variant DNA. J Biol Chem 1980, 255(7):3194–3203.
38. Ruffing M, Zentgraf H, Kleinschmidt JA: Assembly of virus like particles by
recombinant structural proteins of adeno-associated virus type 2 in
insect cells. J Virol 1992, 66(12):6922–6930.
39. Steinbach S, Wistuba A, Bock T, Kleinschmidt JA: Assembly of adeno-
associated virus type 2 capsids in vitro. J Gen Virol 1997,
78(Pt 6):1453–1462.
doi:10.1186/1475-2859-11-124
Cite this article as: Backovic et al.: Capsid protein expression and adeno-
associated virus like particles assembly in Saccharomyces cerevisiae.
Microbial Cell Factories 2012 11:124.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
